ClinicalTrials.gg
Active, not recruitingNCT04232696Updated Nov 3, 2025Results posted

Neuspera's Implantable Sacral Nerve Stimulation System in Patients With Symptoms of Urinary Urgency Incontinence (UUI)

An interventional study of Neuspera Implantable Sacral Nerve Stimulation System in Urinary Urgency Incontinence, sponsored by Neuspera Medical, Inc.. Active, not recruiting at 34 sites in 3 countries. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2025-11-03.

Sponsored by Neuspera Medical, Inc. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
331
Allocation
Not applicable
Ages
22 Years and older
Sex
All
01

Study summary

Prospective, multi-center, single-arm, seamless phase-pivotal study conducted in participants diagnosed with UUI who have failed or could not tolerate more conservative treatment. The trial will be conducted in two phases.

Objective of Phase I: To assess the utilization of the system during the Sacral Nerve Stimulation (SNS) trial period and to help inform the length of hours of daily stimulation to be used in Phase II of the trial.

Objective of Phase II: To assess the safety and efficacy of the Neuspera SNS System at 6-months for the primary efficacy endpoint and at 12 months for secondary safety and efficacy endpoints.

Read the detailed description

Neuspera's Implantable Sacral Nerve Stimulation (SNS) System is indicated to treat participants with UUI who have failed or could not tolerate more conservative treatments.

The study will be conducted in two phases: Phase I of the study will be conducted at up to 9 clinical study sites in the US and Europe. Phase II of the study will be conducted in up to 35 clinical sites in the US and Europe, inclusive of the Phase I centers.

Prospective, multi-center, single-arm, seamless phase-pivotal study. Objective of Phase I: To assess the utilization of the system during the Sacral Nerve Stimulation (SNS) trial period and to help inform the length of hours of daily stimulation to be used in Phase II of the trial.

Objective of Phase II: To assess the safety and efficacy of the Neuspera SNS System at 6-months for the primary efficacy endpoint and at 12 months for secondary safety and efficacy endpoints. All participants will receive the same length of device stimulation as determined in Phase I testing.

Phase I will enroll up to 55 participants. Phase II will enroll up to 255 participants.

02

Conditions studied

  • Urinary Urgency Incontinence

Keywords

  • UUI
03

In context

Lead sponsor

Neuspera Medical, Inc. is the lead sponsor of 5 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has a (BMI) between 18 and 40.
  2. Has a diagnosis of UUI for greater than or equal to 6 months prior to the screening baseline visit date.
  3. Has failed or was not a candidate for more conservative treatment (e.g. pelvic floor training, biofeedback, behavioral modification).
  4. Has failed or could not tolerate (stopped taking medication due to lack of efficacy or intolerable side effects) or not a good candidate for (as determined by treating physician) at least one (1) antimuscarinic or β3 adrenoceptor agonist medication.
  5. Has a diagnosis of UUI with at least 4 UUI episodes on a 72-hour diary, and minimum of one (1) UUI episode per 24-hour period.

Exclusion criteria

Exclusion Criteria:

  1. Has a of greater than 8 percent, or has diabetes mellitus with glucosuria.
  2. Has diabetic neuropathy.
  3. Has interstitial cystitis or bladder pain syndrome as defined by either American Urological Association (AUA) or European Association of Urology (EAU) guidelines, chronic pelvic pain or recurrent symptomatic urinary tract infections.
  4. Has neurogenic bladder dysfunction such as traumatic or atraumatic myelopathy, multiple sclerosis, Parkinsonism, or history of cerebrovascular accident.
  5. Has documented urinary retention within 6 months prior to the screening baseline visit date.
  6. Has bladder outlet obstruction.
  7. Is a subject with a mechanical obstruction such as benign prostatic hypertrophy, urethral stricture or cancer.
  8. Has primary stress incontinence or mixed incontinence where the stress component predominates or has been treated surgically for stress urinary incontinence within 6 months prior to the screening baseline visit date.
  9. Has received tibial nerve stimulation (TNS) in the past 3 months for the treatment of overactive bladder or unwilling to stay off TNS therapy for 12-month period following implant.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
331 participants (actual)

Study arms

  • Experimental
    Neuspera Implantable Sacral Nerve Stimulation System

    Implantation of the stimulator.

    Device: Neuspera Implantable Sacral Nerve Stimulation System

Interventions

  • DeviceNeuspera Implantable Sacral Nerve Stimulation System

    Stimulation of the Sacral Nerve.

06

What researchers measure

Primary outcomes

  1. Primary Efficacy Endpoint: Percentage of Participants Who Experience a 50 Percent or More Change in Urinary Urgency Incontinence Episodes.

    Change in Urinary Urgency Incontinence episodes at six months, relative to the number of Urinary Urgency Incontinence episodes at baseline.

    Time frame: 6 months

  2. Primary Safety Endpoint: Defined as the Proportion of Subjects Experiencing a Device-related Serious Adverse Events.

    The analysis of the endpoint is the proportion of subjects experiencing a device-related SAE through the 6-month post-implant.

    Time frame: 6 months

Secondary outcomes

  1. Phase II Change in Quality of Life: Measured From Baseline as Measured and Assessed by the Total and Subset International Consultation on Incontinence Questionnaire Overactive Bladder Quality of Life Score.

    Change from baseline in qualify of life. Total score (25 min,160 max) with higher score indicating increase impact on quality of life.

    Time frame: 6 and 12 months

  2. Phase II Efficacy Endpoint: Defined as the Percentage of Participants Who Experience a 50 Percent or More Change in Urinary Urgency Incontinence.

    Change in Urinary Urgency Incontinence episodes at 12 months post-completion of the trial phase, relative to the number of Urinary Urgency Incontinence episodes at baseline prior to the trial phase.

    Time frame: 12 months

  3. Phase II Urgent Voids Per Day

    Change in urgent voids per day from baseline to 6-months and 12 months. Calculated across all diary episodes with at least mild urgency.

    Time frame: 6 and 12 months

  4. Phase II Change in Average Number of Daily Voids

    Change in average number of daily voids from baseline in subjects with at least 8 voids at baseline.

    Time frame: 6 and 12 months

  5. Phase II Comprehensive Summary of All Adverse Events

    The incidence of adverse events will be reported.

    Time frame: 6 and 12 months

  6. Phase II Device Parameter Information Collected

    Device amplitude will be collected in volts.

    Time frame: 6 and 12 months

  7. Phase II Physician and Subject User Experience Questionnaire

    Physician and subject satisfaction will be obtained by answering questions on the use of the device using a five point scale:strongly agree, agree, neither agree nor disagree, disagree, strongly disagree. Answers towards strongly agree indicate a better outcome.

    Time frame: 6 and 12 months

  8. Phase II Urinary Tract Symptoms Questionnaire: International Consultation on Incontinence Questionnaire Female & Male Lower Urinary Tract Symptoms Modules

    Change in female lower urinary tract symptoms questionnaire. Male questionnaire score ranges from 0-52 and female questionnaire score ranges from 0-48. Higher number indicates worse outcome.

    Time frame: 6 and 12 months

  9. Phase II Safety Endpoint: Defined as the Incidence of Device-related Serious Adverse Events in the Post-trial Period Follow-up.

    The number of serious adverse events related to the device.

    Time frame: 12 months

  10. Phase II Urinary Output

    Total urinary output as measured by 72-hour bladder diary.

    Time frame: 6 and 12 months

  11. Phase II Fecal Incontinence Measured by Wexner Scale

    Wexner scale total points 0-20, higher the score the worse the outcome. Fecal incontinence as measured by the Wexner Scale compared to baseline.

    Time frame: 6 months

  12. Phase II Patient Global Impression of Improvement

    Patient Global Impression of Improvement measured after implant during follow-up. Single question answered on a seven point scale: very much better, much better, a little better, no change, a little worse, much worse, very much worse. Selection of very much better is the best outcome.

    Time frame: 6 and 12 months

07

Results

Posted Nov 3, 2025

Participant flow

Participant flow — Overall Study
MilestonePhase I, Neuspera Implantable Sacral Nerve Stimulation SystemPhase II, Neuspera Implantable Sacral Nerve Stimulation System
Started39130
Completed34111
Not completed519
Withdrew: Implant attempted but not completed52
Withdrew: Not satisfied with therapy outcome08
Withdrew: Adverse event03
Withdrew: Withdrawal by subject03
Withdrew: Missed visit02
Withdrew: Other reason01

Outcome measures

PrimaryPrimary Efficacy Endpoint: Percentage of Participants Who Experience a 50 Percent or More Change in Urinary Urgency Incontinence Episodes.

Change in Urinary Urgency Incontinence episodes at six months, relative to the number of Urinary Urgency Incontinence episodes at baseline.

Time frame:
6 months
Reported as:
Number · percentage of participants
Primary Efficacy Endpoint: Percentage of Participants Who Experience a 50 Percent or More Change in Urinary Urgency Incontinence Episodes.
percentage of participantsPhase I, Neuspera Implantable Sacral Nerve Stimulation SystemPhase II, Neuspera Implantable Sacral Nerve Stimulation System
Primary Efficacy Endpoint: Percentage of Participants Who Experience a 50 Percent or More Change in Urinary Urgency Incontinence Episodes.93.3 (77.9 to 99.2)95.5 (89.8 to 98.5)
PrimaryPrimary Safety Endpoint: Defined as the Proportion of Subjects Experiencing a Device-related Serious Adverse Events.

The analysis of the endpoint is the proportion of subjects experiencing a device-related SAE through the 6-month post-implant.

Time frame:
6 months
Reported as:
Count of participants · Participants
Primary Safety Endpoint: Defined as the Proportion of Subjects Experiencing a Device-related Serious Adverse Events.
ParticipantsPhase I, Neuspera Implantable Sacral Nerve Stimulation SystemPhase II, Neuspera Implantable Sacral Nerve Stimulation System
Primary Safety Endpoint: Defined as the Proportion of Subjects Experiencing a Device-related Serious Adverse Events.00
SecondaryPhase II Change in Quality of Life: Measured From Baseline as Measured and Assessed by the Total and Subset International Consultation on Incontinence Questionnaire Overactive Bladder Quality of Life Score.

Change from baseline in qualify of life. Total score (25 min,160 max) with higher score indicating increase impact on quality of life.

Time frame:
6 and 12 months

Results for this outcome have not been posted.

SecondaryPhase II Efficacy Endpoint: Defined as the Percentage of Participants Who Experience a 50 Percent or More Change in Urinary Urgency Incontinence.

Change in Urinary Urgency Incontinence episodes at 12 months post-completion of the trial phase, relative to the number of Urinary Urgency Incontinence episodes at baseline prior to the trial phase.

Time frame:
12 months

Results for this outcome have not been posted.

SecondaryPhase II Urgent Voids Per Day

Change in urgent voids per day from baseline to 6-months and 12 months. Calculated across all diary episodes with at least mild urgency.

Time frame:
6 and 12 months

Results for this outcome have not been posted.

SecondaryPhase II Change in Average Number of Daily Voids

Change in average number of daily voids from baseline in subjects with at least 8 voids at baseline.

Time frame:
6 and 12 months

Results for this outcome have not been posted.

SecondaryPhase II Comprehensive Summary of All Adverse Events

The incidence of adverse events will be reported.

Time frame:
6 and 12 months

Results for this outcome have not been posted.

SecondaryPhase II Device Parameter Information Collected

Device amplitude will be collected in volts.

Time frame:
6 and 12 months

Results for this outcome have not been posted.

SecondaryPhase II Physician and Subject User Experience Questionnaire

Physician and subject satisfaction will be obtained by answering questions on the use of the device using a five point scale:strongly agree, agree, neither agree nor disagree, disagree, strongly disagree. Answers towards strongly agree indicate a better outcome.

Time frame:
6 and 12 months

Results for this outcome have not been posted.

SecondaryPhase II Urinary Tract Symptoms Questionnaire: International Consultation on Incontinence Questionnaire Female & Male Lower Urinary Tract Symptoms Modules

Change in female lower urinary tract symptoms questionnaire. Male questionnaire score ranges from 0-52 and female questionnaire score ranges from 0-48. Higher number indicates worse outcome.

Time frame:
6 and 12 months

Results for this outcome have not been posted.

SecondaryPhase II Safety Endpoint: Defined as the Incidence of Device-related Serious Adverse Events in the Post-trial Period Follow-up.

The number of serious adverse events related to the device.

Time frame:
12 months

Results for this outcome have not been posted.

SecondaryPhase II Urinary Output

Total urinary output as measured by 72-hour bladder diary.

Time frame:
6 and 12 months

Results for this outcome have not been posted.

SecondaryPhase II Fecal Incontinence Measured by Wexner Scale

Wexner scale total points 0-20, higher the score the worse the outcome. Fecal incontinence as measured by the Wexner Scale compared to baseline.

Time frame:
6 months

Results for this outcome have not been posted.

SecondaryPhase II Patient Global Impression of Improvement

Patient Global Impression of Improvement measured after implant during follow-up. Single question answered on a seven point scale: very much better, much better, a little better, no change, a little worse, much worse, very much worse. Selection of very much better is the best outcome.

Time frame:
6 and 12 months

Results for this outcome have not been posted.

Adverse events

Collected over At least 6 months post-implant. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ph I, Neuspera Implantable Sacral Nerve Stimulation System0/39 (0%)1/39 (2.6%)10/39 (25.6%)
Ph II, Neuspera Implantable Sacral Nerve Stimulation System0/130 (0%)16/130 (12.3%)0/130 (0%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventPh I, Neuspera Implantable Sacral Nerve Stimulation SystemPh II, Neuspera Implantable Sacral Nerve Stimulation System
Numbness and tingling in left footNervous system disorders1/390/130
NephrolithiasisRenal and urinary disorders0/392/130
Abnormal uterine bleedingReproductive system and breast disorders0/392/130
Atrial FibrillationCardiac disorders0/391/130
Intestinal ObstructionGastrointestinal disorders0/391/130
AppendicitisInfections and infestations0/391/130
Breast CellulitisInfections and infestations0/391/130
Ankle FractureInjury, poisoning and procedural complications0/391/130
FallInjury, poisoning and procedural complications0/391/130
Lower Limb FractureInjury, poisoning and procedural complications0/391/130
Most frequent other events
Most frequent other events
EventPh I, Neuspera Implantable Sacral Nerve Stimulation SystemPh II, Neuspera Implantable Sacral Nerve Stimulation System
Implant Site PainGeneral disorders5/39—
Device DislocationProduct Issues3/39—
Muscle TightnessMusculoskeletal and connective tissue disorders2/39—
Device BreakageProduct Issues2/39—

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Phase I: Neuspera Implantable Sacral Nerve Stimulation SystemPhase II: Neuspera Implantable Sacral Nerve Stimulation SystemTotal
Mean59.8 ± 12.660.4 ± 10.260.2 ± 10.8
Sex: Female, Male
Sex: Female, Male(Participants)Phase I: Neuspera Implantable Sacral Nerve Stimulation SystemPhase II: Neuspera Implantable Sacral Nerve Stimulation SystemTotal
Female37128165
Male224
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase I: Neuspera Implantable Sacral Nerve Stimulation SystemPhase II: Neuspera Implantable Sacral Nerve Stimulation SystemTotal
Hispanic or Latino11011
Not Hispanic or Latino38120158
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase I: Neuspera Implantable Sacral Nerve Stimulation SystemPhase II: Neuspera Implantable Sacral Nerve Stimulation SystemTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American156
White38124162
More than one race000
Unknown or Not Reported011
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m2)Phase I: Neuspera Implantable Sacral Nerve Stimulation SystemPhase II: Neuspera Implantable Sacral Nerve Stimulation SystemTotal
Mean30 ± 5.429.5 ± 5.129.6 ± 5.2
08

Study locations

34 sites
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — At this time, there is no plan to share information.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2019 to primary completion in Jul 2024, 55 months.

Results were first posted in Nov 2025, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2019
First posted
Jan 18, 2020
StartActual
Dec 13, 2019
Primary completionActual
Jul 17, 2024
CompletionEst.
Dec 2026
Results first posted
Nov 3, 2025
Last update
Nov 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04232696
Lead sponsor
Neuspera Medical, Inc.
Responsible party
Sponsor
First posted
Jan 18, 2020
Start date
Dec 13, 2019
Primary completion
Jul 17, 2024
Completion
Dec 2026 (estimated)
Results posted
Nov 3, 2025
Last update
Nov 3, 2025

Study contacts

Osvaldo Padron, MD
principal investigator · Florida Urology Partners

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion